Navigation Links
Breast Cancer Vaccine Reduces Cancer Recurrence in Women: Interim Results From Phase 2 Clinical Trial Trend Toward AE37 Vaccine Benefit; Results Presented at SABCS
Date:12/8/2011

WORCESTER, Mass. and TORONTO, Dec. 8, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) today announced that positive interim Phase 2 clinical data from its ongoing study of a novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37) in HER-2 expressing breast cancer patients were presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.  The AE37 vaccine is being developed by its wholly-owned subsidiary, Antigen Express, Inc.

(Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b)

"We are encouraged by the positive interim results in disease-free survival demonstrated in the randomized Phase 2 study with AE37 vaccine, especially in patients with low HER2 expression that are not currently eligible for Herceptin® (trastuzumab; Roche-Genentech)," said Dr. Eric von Hofe, Ph.D., President of Antigen Express.  "While the number of patients with recurrent breast cancer is still too low to demonstrate statistical significance in this ongoing study, we project a sufficient number of events in 2012 and expect to report final results during this period."

The results were presented at SABC by COL George E. Peoples, MD's Cancer Vaccine Development Program on December 7th.  "Women with breast cancers expressing low levels of HER2 do not benefit from targeted HER2 therapies that are currently available," said COL Peoples, a leading researcher in adjuvant breast cancer vaccine development. "Our research is focused on reducing the recurrence of cancer using a woman's own immune system to fight her disease, including breast cancers that express low levels of HER2.  The AE37 vaccine is based on over 5 years of research and continues to show promise in a well-designed and ongoing randomized Phase 2 clinical trial that if positive, will allow rapid transition to Phase 3."'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genomic Health Announces Positive Results of First Clinical Outcomes Study for Biomarker Discovery Using Next Generation Sequencing at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium
2. New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth
3. MarginProbe® Pivotal Study Presented at San Antonio Breast Cancer Symposium
4. Survival Benefit With Syndax Pharmaceuticals Entinostat Maintained in Women with Advanced Breast Cancer
5. Agendia Introduces the SYMPHONY™ Breast Cancer Profile With Paraffin Embedded Tissue
6. BSGI/MBI Proven to Be Equivalent to MRI in the Detection of Breast Cancer
7. BSGI/MBI Enhances Pre-Surgical Planning For Patients With Newly Diagnosed Breast Cancer
8. Genomic Health Announces Presentation of Sixteen Oncotype DX Studies at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium
9. U-Systems Launches somo-v Platinum Automated Breast Ultrasound System at RSNA
10. Biodesix Announces New VeriStrat® Data to be Presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium
11. Generex Subsidiary Antigen Express to Present AE37 Cancer Vaccine Phase 2 Clinical Data at 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014   LabStyle Innovations ... Solution, today announced the appointment of Professor ... of its Board of Directors. Prof. ... business experience to LabStyle as an entrepreneur, venture ... and corporate governance expert. He currently serves on ...
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
Breaking Medicine Technology:LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... --  Empire Genomics today announced that it has ... portfolio for the Japanese market.  The deal represents Empire,s international ... "We are excited to have such a proven and expert ... access to our broad genomic product and service portfolio," said ...
... MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. ... Administration (FDA) for its Abbreviated New Drug Application (ANDA) for ... mg, 15 mg, and 20 mg. This product is the ... which is indicated for the treatment of schizophrenia and the ...
Cached Medicine Technology:Empire Genomics Chooses Funakoshi as Japan Distributor 2Mylan Launches Generic Version of Zyprexa® Tablets 2
(Date:7/10/2014)... New York City, NY (PRWEB) July 10, 2014 ... to the life sciences industry, has launched a new ... mobile responsiveness, as well as increased access to the ... “The new cbpartners.com provides an ideal platform to showcase ... global health access issues,” says CBPartners’ Chief Executive Officer, ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 ... the latest results of the 4th “Trending in ... suite model. , Every day multinational corporations ... contracts, expense forms etc. To meet this challenge, ... (S2P) suites which can be defined as a ...
(Date:7/10/2014)... -- Adults with dyslexia are more likely to report ... than people who don,t have the learning disorder, according ... up to 10 percent of people, causes problems with ... adults with this condition said they suffered physical abuse ... without dyslexia. "Even after accounting for age, race, ...
(Date:7/10/2014)... HealthDay Reporter THURSDAY, July 10, 2014 ... use of calorie information on menus, if it,s available, to ... U.S. study. Women in particular review the menu labeling, ... with the U.S. Centers for Disease Control and Prevention. ... to help choose their meal, compared with just under half ...
(Date:7/10/2014)... the amount of alcoholic beverages consumed, even for ... reduced risk of coronary heart disease, lower body ... a new multi-center study published in The ... of Medicine at the University of Pennsylvania. The ... suggest that consuming light-to-moderate amounts of alcohol (0.6-0.8 ...
Breaking Medicine News(10 mins):Health News:CBPartners Announces New Website 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 3Health News:Researchers See Link Between Dyslexia, Abuse 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 3Health News:New study shows drinking alcohol provides no heart health benefit 2
... March 26 The statement below is attributable ... Association. This statement is being issued in response to ... England Journal of Medicine about prostate-specific antigen ... great interest the coverage surrounding the two studies about ...
... Percent of Surveyed MCO Pharmacy Directors Say They ... Idiopathic Arthritis and Pediatric Crohn,s Disease, According to ... 26 Decision Resources, one of the world,s ... healthcare issues, finds that 30 percent of surveyed ...
... radicals, researchers say , , THURSDAY, March 26 (HealthDay ... children,s lung growth and function, as well as ... University of Southern California researchers. , "Many factors ... variation and environmental exposures such as tobacco smoke ...
... (ASCTA) is formed in response to the Food and Drug Administration,s ... body are drugs, a position the ASCTA opposes. This physician ... adult stem cell therapy to their patients more quickly. , ... ...
... Strategic Cost Management Expertise with Hospitals Nationwide to Help ... An exclusive group of hospital CEOs from ... to Texas, and California to the Carolinas, will convene ... summit to address the implications of the economic stimulus ...
... March 26 Birner Dental Management Services, Inc. ... of PERFECT TEETH dental practices, ... Total dental group practice revenue decreased $371,000, or .6%, ... to $34.5 million. The Company,s earnings before interest, taxes, ...
Cached Medicine News:Health News:American Urological Association Statement in Support of Prostate-Specific Antigen Testing 2Health News:American Urological Association Statement in Support of Prostate-Specific Antigen Testing 3Health News:As a Result of the FDA Investigation Into TNF-Alpha Inhibitors, 30 Percent of Surveyed Rheumatologists Have Altered Their Prescription Patterns for Juvenile Idiopathic Arthritis 2Health News:As a Result of the FDA Investigation Into TNF-Alpha Inhibitors, 30 Percent of Surveyed Rheumatologists Have Altered Their Prescription Patterns for Juvenile Idiopathic Arthritis 3Health News:Genes May Boost Harm to Kids From Secondhand Smoke 2Health News:Physician Group Opposes FDA's Position on Adult Stem Cells 2Health News:Physician Group Opposes FDA's Position on Adult Stem Cells 3Health News:Healthcare CEO Summit Addressing Strategic Implications of Economic Stimulus Package to be Hosted by InfoLogix 2Health News:Healthcare CEO Summit Addressing Strategic Implications of Economic Stimulus Package to be Hosted by InfoLogix 3Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 2Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 3Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 4Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 5Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 6Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 7Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 8Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 9
... endoscope is the first Video ... instrument incorporates a 2.0mm instrument ... insertion tube. The slim size ... easy introduction even through areas ...
... Used for temporary internal drainage from ... Supplied sterile in peel-open packages. Intended ... is advised; C-Flex® and Sof-Flex® stents ... six (6) months; silicone stents must ...
... internal drainage from the ureteropelvic junction to ... for ease of placement and patient compliance. ... for repositioning and ease of removal. AQ® ... that when activated, attracts and holds water ...
... Double Pigtail Ureteral Stents have an ... maximizes migration. They also feature unique ... cost savings. Each Classic Double PigTail ... Double PigTail Ureteral Stent with attached ...
Medicine Products: